LL-37 vs Thymosin Alpha-1
Updated September 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of LL-37 and Thymosin Alpha-1 (also searched as Thymosin Alpha-1 vs LL-37) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
LL-37 centers on healing, while Thymosin Alpha-1 leans toward inflammation. On indexed research, LL-37 is ahead (LL-37: 32 studies, Human evidence; Thymosin Alpha-1: 21, Human clinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •LL-37 is strongest for healing; Thymosin Alpha-1 for inflammation.
- •Evidence: LL-37 Human evidence (32 studies) vs Thymosin Alpha-1 Human clinical (21).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Immune modulation | Infections and inflammatory diseases
LL-37 vs Thymosin Alpha-1: side-by-side
| Metric | LL-37 | Thymosin Alpha-1 |
|---|---|---|
| Class | Immune | Immune |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Human clinical |
| Studies indexed | 32 | 21 |
| Research level | Well Studied | Well Studied |
| Strongest effect | Healing & recovery | Inflammation & immune |
| Healing & recovery | 4.0▲ | 3.0 |
| Muscle & body comp | 1.0▲ | 0.0 |
| Metabolic & appetite | 2.0▲ | 1.0 |
| Neuro & mood | 1.0▲ | 1.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 4.0▲ | 4.0▲ |
| Skin & aesthetics | 2.0▲ | 0.0 |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | LL-37 | Thymosin Alpha-1 |
|---|---|---|
| Mechanism | Disrupts microbial membranes, leading to cell lysis | Enhances T-cell function and promotes maturation of immune cells |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is LL-37?
LL-37 is a human cathelicidin antimicrobial peptide that plays a significant role in the innate immune response. It exhibits a range of biological activities, including antimicrobial, immunomodulatory, and wound healing properties. LL-37 is produced by various cells, including epithelial cells and neutrophils, and is known to interact with a variety of pathogens, including bacteria, viruses, and fungi.
Full LL-37 profile, mechanism & studies →What is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1) is a peptide that plays a crucial role in modulating immune responses and has been investigated for its potential therapeutic applications in various conditions, including infections and inflammatory diseases.
Full Thymosin Alpha-1 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | LL-37 | 4.0/5 effect signal |
| Muscle | LL-37 | 1.0/5 effect signal |
| Metabolic | LL-37 | 2.0/5 effect signal |
| Neuro | Even | Both ~1.0/5 |
| Inflammation | Even | Both ~4.0/5 |
| Skin | LL-37 | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack LL-37 and Thymosin Alpha-1?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
LL-37 vs Thymosin Alpha-1: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
LL-37 has 32 approved studies indexed (Human evidence), and Thymosin Alpha-1 has 21 (Human clinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is LL-37 or Thymosin Alpha-1 better?
It depends on your goal. LL-37 is strongest for healing; Thymosin Alpha-1 for inflammation. LL-37 has more indexed studies (32). See the goal-by-goal breakdown above.
Is LL-37 or Thymosin Alpha-1 better for weight loss?
LL-37 shows the stronger metabolic & appetite profile (2.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is LL-37 or Thymosin Alpha-1 better for muscle?
LL-37 leads on the muscle & body-composition axis (1.0/5).
Which has more research, LL-37 or Thymosin Alpha-1?
LL-37 has 32 approved studies indexed (Human evidence); Thymosin Alpha-1 has 21 (Human clinical). Higher counts mean more to read, not proven superiority.
Can you stack LL-37 and Thymosin Alpha-1?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of LL-37 vs Thymosin Alpha-1?
LL-37: no community-reported effects logged yet. Thymosin Alpha-1: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is LL-37 or Thymosin Alpha-1 FDA-approved?
LL-37 is a research-use compound and is not FDA-approved. Thymosin Alpha-1 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Thymosin Alpha-1 better than LL-37?
For inflammation, Thymosin Alpha-1 has the edge; for healing, LL-37 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
LL-37 and Thymosin Alpha-1 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed September 21, 2026.